Vivesto (VIVE)

Executive Summary

Vivesto AB is a Swedish drug development company founded in 2018, specializing in small molecule therapies for hard-to-treat cancers in both human and veterinary medicine. Headquartered in Uppsala, the company advances proprietary candidates from early research through clinical proof-of-concept, with a strategy to outlicense or partner for late-stage development and commercialization. Vivesto's approach leverages deep expertise in oncology to address significant unmet medical needs, positioning it as a potential player in the precision oncology space. While the company is currently in early clinical stages, its focus on differentiated mechanisms and validated targets offers a pathway to value creation through strategic collaborations or further clinical milestones. Although Vivesto has not yet disclosed detailed pipeline updates, the company's recent progress in preclinical studies suggests near-term catalysts could include the initiation of first-in-human trials or biomarker data readouts. The management team's experience and the company's lean operating model provide a disciplined framework for execution. However, given the early stage and inherent risks of oncology drug development, the near-term upside is contingent on successful clinical execution and partnership opportunities. The conviction score reflects these balancing factors, with potential for re-rating upon positive data or strategic deals.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1 Clinical Trial for Lead Oncology Candidate50% success